This $1,000 Test Finds Cancer In Blood | CRC Rates Drop 25% Over 30 Years
Praveen Suthrum
Cofounder, NextServices | Author, The Shift, Scope Forward | GI Mastermind
Healthcare practices may increase patient volume in clinics to compensate for decreased reimbursements, potentially reducing individual patient care time.
Doctors, researchers and patient advocates are excited about a new blood test that promises to detect cancer early. They disagree about whether you should actually use it yet.
The growing trend of physicians choosing employment over private practice due to economic challenges and administrative burdens, with many employed physicians finding satisfaction in their stable income and work-life balance.
Three controversial trends: changing recommendations for cancer screenings, the challenges of prior authorizations, and the increasing use of artificial intelligence in gastroenterology.
Mass General Hospital's two-year data analysis shows that approximately 60% of real-world Mahana IBS program users reported significantly reduced IBS symptom severity.
The overall mortality reduction was 26%—from 20 per 100,000 to 14.8 per 100,000—but the greatest declines, averaging about 40%, occurred in northern states, such as Massachusetts, New York, and the District of Columbia.
The evolving landscape of gastroenterology in the United States, exploring historical decisions, changing demographics, and the impact on physician salaries.
A next-generation, multitarget stool DNA test detected colorectal cancer with 94% sensitivity and 91% specificity, outperforming fecal immunochemical testing, according to data.
Increased prior authorizations in 2023 pose a significant challenge to the gastroenterology industry, potentially hindering patient care efficiency.
The program, which runs up to 15 weeks, guides users through skill-building exercises aimed at retraining the connection between the mind & gut to ease GI symptoms and improve quality of life.
VolitionRX introduces a cancer detection method that physically isolates tumor-derived circulating DNA fragments from blood, potentially revolutionizing cancer diagnosis with high accuracy and cost-effectiveness.
GI OnDEMAND? partners with GI Psychology LLC, enhancing its platform to provide nationwide access to specialized gut-brain therapists for gastrointestinal health conditions.
Motus GI Holdings, Inc. receives FDA clearance for its advanced Pure-Vu EVS Gastro and Gen 4 Colon system, aiming to enhance endoscopic outcomes and address the needs of patients with upper GI bleeds.
For weekly gastroenterology business/tech updates directly in your inbox, subscribe to the?Scope Forward newsletter.